Loading…

Cardinal HealthCAHCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Distributors

Major US distributor of pharmaceuticals and medical-surgical products to pharmacies, hospitals and labs, plus own-brand medical products.

Momentum leader 92
Mkt cap
$64.3B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$444M
20-day average traded
Fwd P/E
21.1×
forward earnings
ROIC−WACC
n/a
WACC 7.5%
Hurdle
-2 pp
Req g minus delivered
Official | Implied
BBB / A-
agencies · bond market
Next earnings
78 days
4 Feb 2027
Close · USD$278.32
1D-0.3%
1W+0.3%
1M+8.1%
3M+21.8%
6M+40.0%
YTD+36.4%
1Y+36.0%
ATR %2.2%
Beta-0.00
52w lowhigh2.8% off high

What Cardinal Health does

Major US distributor of pharmaceuticals and medical-surgical products to pharmacies, hospitals and labs, plus own-brand medical products.

Resells branded and generic drugs to pharmacies and hospitals for a thin margin, and earns more from generics through Red Oak Sourcing, a purchasing venture with CVS. A few large pharmacy chains, notably CVS and Walgreens, provide a big share of sales. Its Medical segment sells own-brand gloves, gowns and kits and has been rebuilding margins.

Products and services

  • Pharmaceutical distribution
  • Medical (surgical/lab) distribution & own-brand products
  • Specialty/nuclear pharmacy services

Customers

  • Retail/independent pharmacies
  • Hospitals
  • Ambulatory surgery centers
  • Clinical labs

Where it sits in the supply chain

  • Healthcare
  • Pharmaceutical/medical distribution
  • Wholesale drug + medical products…

What could go right

  • Specialty pharmacy/biosimilar growth
  • Medical segment margin recovery

What could go wrong

  • Thin distribution margins
  • Opioid litigation liabilities

Moat: narrow (scale, distribution). National-scale logistics network across both drug and medical-surgical supply chains.

Headquarters: Dublin, Ohio, USA · Founded: 1971 · Employees: 63,900

Named competitors

Cardinal Health at a glance

Size Cardinal Health (CAH) is a United States Health Care company (Medical Distributors) with a market value of $64.3B, the 205th largest of 3,085 United States companies the cockpit tracks. Shares closed at $278.32 on 18 Nov 2026.

Performance Over six months the shares gained 40.0%, against +11.7% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 10.0% over the last twelve months (peer median +6.2%); the operating margin is 1.3% (peer median 2.9%).

Valuation It trades at 21.1× forward earnings against a peer median of 17.0× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -2 pp: the price already allows for a slowdown.

Credit Cardinal Health has 13 bonds outstanding ($7.98B), rated BBB by the agencies and trading like A- at a weighted spread of 91 bp.

Short interest Short interest is 3.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CAH 139Peer median 112
Six months, rebased to 100: Cardinal Health against the median of its 20 peers (local-currency closes).

Cardinal Health financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$258B$254B$223B$227B$205B
Revenue growth—+14%-2%+11%—
Gross profit$9.68B$9.40B$7.86B$7.15B$6.59B
EBITDA$4.38B$4.22B$3.26B$2.86B$2.48B
Net income$1.82B$1.71B$1.56B$852M$330M
Free cash flow$4.90B$4.53B$1.85B$3.25B$2.36B
Capital expenditure$698M$649M$547M$511M$481M
Total debt$8.81B$9.95B$9.35B$5.61B$5.18B

Quarterly statements and history in the cockpit →

Cardinal Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%CORMCKHSIC1099DKSHGALE6009987459AMP33492784ASKER00893099878129RDC33606005877476DOCMCAH6-month return →1-month return →
Up and to the right = strong over both horizons. Cardinal Health is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%10×20×CORMCKHSIC1099DKSHGALE6009987459AMP33492784ASKER9987812933606005877476CAHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cardinal Health is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%CORMCKHSIC1099DKSHGALE6009987459AMPASKER00893099873360CAHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cardinal Health is the large dot.

Cardinal Health competitors and peer comparison

Head to head with its named competitors (CAH vs MCK vs COR vs MDLN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cardinal Health CAH$64.3B+40%+10%1%21.1×7.8%
McKesson MCK$125B+44%+8%2%22.1×-5.5%
Cencora COR$66.5B+32%+5%1%17.7×-1.2%
Medline MDLN$51.5B+8%+12%6%25.6×15.9%

How Cardinal Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cardinal Health against its 20 peers (data as of 18 Nov 2026)
MeasureCAHPeer medianRank in peer set
1-month return+8.1%+1.8%4th highest of 21
6-month return+40.0%+11.7%5th highest of 21
Distance from 52-week high-2.8%-13.2%2nd highest of 21
Revenue growth (TTM)+10.0%+6.2%4th highest of 21
Operating margin1.3%2.9%6th lowest of 21
Forward P/E21.1×17.0×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)7.8%-1.2%3rd most demanding of 18
Growth delivered (Del g)+9.4%+5.4%6th highest of 18
Hurdle (Req g minus delivered)-1.5 pp-8.1 pp4th most demanding of 18
Net debt / EBITDA0.8×0.6×9th most indebted of 18
Bond spread91 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cardinal Health CAHUnited States$64.3B+40%+10%1%21.1×7.8%+9.4%
Cencora CORUnited States$66.5B+32%+5%1%17.7×-1.2%+9.5%
McKesson MCKUnited States$125B+44%+8%2%22.1×-5.5%+11.1%
Henry Schein HSICUnited States$9.47B+17%+6%6%14.7×10.2%+5.4%
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a

Cardinal Health bonds and credit

Cardinal Health has 13 bonds outstanding with $7.98B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.83%, a spread of 91 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Cardinal Health's main competitors?
Named competitors: McKesson Corporation (MCK), Cencora (COR), Medline (MDLN), Owens & Minor (private or unlisted). The cockpit's measured peer set (industry) also includes Cencora (COR), McKesson (MCK), Henry Schein (HSIC), Sinopharm (1099.HK), DKSH (DKSH.SW), Galenica (GALE.SW).
Is Cardinal Health expensive compared with its peers?
On forward p/e it trades at 21.1× against a peer median of 17.0×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Cardinal Health stock performed?
Over six months to 18 Nov 2026 the shares returned +40.0% against +11.7% for the median peer; over one year +36.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.